Clinical Trial Update: Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Phase II trial of alisertib (MLN8237) in salvage malignant mesothelioma has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Malignant Mesothelioma

Drugs mentioned

• Alisertib (alisertib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer, Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2022-10-04